On 22 July 2k19, ASML Holding N.V. (NASDAQ:ASML) closed with gain/decline of +1.84% to $227.74. Recent traded volume was 742,848 shares versus to it an average volume of 641,887 shares. The company holds 425.66M shares outstanding and market cap of 96.353B. The stock day range was recorded between a low of $225.29 and a high $228.12.
ASML Holding N.V. (ASML) publishes its 2k19 second-quarter results.
Q2 2k19 product and business highlights
Outlook
For the third quarter of 2k19, ASML expects net sales about EUR 3.0B, and a gross margin of between 43 percent and 44 percent. ASML also expects R&D costs of about EUR 495M, and SG&A costs of about EUR 125M. Our estimated annualized effective tax rate is about 9 percent for 2k19.
Update share buyback program
As part of ASML’s financial policy to return excess cash to shareholders through dividends and regularly timed share buybacks, in January 2k18 ASML reported its intention to purchase up to EUR 2.5B of shares, to be executed within the 2k18–2k19 time frame. ASML intends to cancel these shares after repurchase, with the exception of up to 2.4M shares, which will be used to cover employee share plans.
Through June 30, 2k19, ASML has purchased 7.5M shares under this program for a total consideration of EUR 1.2B.
Analyst recommendation for this stock stands at 1.80. The P/E ratio was recorded at 37.22. The volatility in the previous week has experienced by 1.56% and observed of 1.28% in the previous month. 17.10% ownership is held by institutional investors while insiders hold ownership of 0.40%.
ASML Holding N.V. (ASML) publishes its 2k19 second-quarter results.
Q2 2k19 product and business highlights
- For EUV, on the NXE:3400C, we recently demonstrated >170 wafers per hour at ASML as well as >2,000 wafers per day under consumer memory production conditions.
- ASML and Mitsui Chemicals have agreed that ASML will license the EUV pellicle assembly technology to Mitsui Chemicals. Mitsui Chemicals is able to assemble and sell pellicles in high volume to our lithography consumers. In parallel, ASML will continue to develop next generations of pellicle membranes with its partners, which is predictable to enable improved performance of EUV pellicles.
Outlook
For the third quarter of 2k19, ASML expects net sales about EUR 3.0B, and a gross margin of between 43 percent and 44 percent. ASML also expects R&D costs of about EUR 495M, and SG&A costs of about EUR 125M. Our estimated annualized effective tax rate is about 9 percent for 2k19.
Update share buyback program
As part of ASML’s financial policy to return excess cash to shareholders through dividends and regularly timed share buybacks, in January 2k18 ASML reported its intention to purchase up to EUR 2.5B of shares, to be executed within the 2k18–2k19 time frame. ASML intends to cancel these shares after repurchase, with the exception of up to 2.4M shares, which will be used to cover employee share plans.
Through June 30, 2k19, ASML has purchased 7.5M shares under this program for a total consideration of EUR 1.2B.
Analyst recommendation for this stock stands at 1.80. The P/E ratio was recorded at 37.22. The volatility in the previous week has experienced by 1.56% and observed of 1.28% in the previous month. 17.10% ownership is held by institutional investors while insiders hold ownership of 0.40%.
)
